プレスリリース
Quintiles Launches New Capabilities to Enable Biopharma Success in Asia
Press Release —
February 8, 2012 – Quintiles launched two unique services that will help increase the probability of success in developing and commercializing new medications in Asia.
Oncology Experience
Brochure — Quintiles acquires Outcome to offer full spectrum of inventional and observational research. Together, we offer the expertise and experience in real-world and late phase research
Quintiles Highlights
Brochure — Turkey has outstanding access to patients with a population of almost 75 million. Quintiles recent experience demonstrates Turkey provides rapid patient enrollment with high patient retention rates and remains an emerging market with few competing studies – becoming a major hub for patient recruitment.
India Central Laboratory Services
Brochure — Quintiles offers a local presence in India alongside seven other wholly owned labs and two affiliates strategically located around the world. Over time, we have developed key relationships in local regulatory and shipping communities, giving us the ability to support investigators in India, elsewhere in Asia or around the globe.
Watch Video
Quintiles understands stakeholder expectations so you can integrate commercial insights into the development process.
Middle East Oncology capabilities
Brochure — Outstanding access to patients in the Middle East region with a population of over 200 million means this is an important emerging region for the biopharmaceutical industry and Quintiles has a proven track record of rapid patient enrollment with high patient retention rates.
South Africa Central Laboratory Services
Brochure — Quintiles offers a local presence in Africa alongside seven other wholly owned labs and two affiliates strategically located around the world. Over time, we have developed key relationships in local regulatory and shipping communities, giving us the ability to support investigators in Africa or around the globe.
Podcasts
Subscribe to our podcasts on iTunes.
